Skip to main content

Table 2 Baseline characteristics

From: A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma

  Placebo (n = 166) Grass AIT (n = 163)
Female, no. (%) 88 (53%) 88 (54%)
Race, no. (%)   
  White 134 (81%) 134 (82%)
  Black 21 (13%) 21 (13%)
  Hispanic/Latino 6 (4%) 4 (2%)
  Non-smoker 121 (73%) 128 (79%)
Previous smoker, no. (%) 24 (14%) 26 (16%)
Smoker, no. (%) 21 (13%) 9 (6%)
Age, y   
  Mean (SD) 35.9 (11.7) 35.9 (11.7)
  Range 18-62 18-65
Subjects with asthma, no. (%) 43 (26%) 46 (28%)
Sensitive to non-grass allergens per skin prick, no. (%)   
  White oak 74 (45%) 75 (46%)
  White birch 84 (51%) 87 (53%)
  Animal hair/dander (cat) 77 (46%) 79 (48%)
  House dust mite 86 (52%) 93 (57%)
Mean duration of pre-treatment (weeks), [range] 16.2 [5.9, 23.9] 16.3 [6.4, 23.7]
  1. AIT Allergy immunotherapy tablet, DSS Daily symptom score, SD Standard deviation.